This isn't a major paper, but it's an interesting jumping-off point for three different topics:

- Accuracy of RATs—in practice
- Understanding what descriptive (incl. Bayesian) statistics mean
- HOW rapid tests work

Here's a thread written for a general audience!

1/ Published Aug 2, 2024 in PLOS ONE: "Evaluation of COVID-19 rapid antigen test against polymerase chain reaction test in immunocompromised patients"  Abstract: "... Patients with Ct value less than 20, had the highest detection rate which is consistent with other studies in the literature. The sensitivity and specificity of Panbio Rapid Antigen testing were of 69.9% and 100%, respectively. A correlation between age group and false negative results could not be made, but a correlation between Ct value and false negative result was noticed, Ct value was directly related to false...
This study was conducted from January 2020 to June 2021 using admission screening swabs from 556 oncology patients at a single hospital in Jerusalem.

The patients in this study were swabbed for both PCR and RAT, allowing for comparison of the detection ability.

2/ "Materials and methods Study design  This prospective study was conducted on 556 patients evaluated at Augusta Victoria Hospital (AVH) between January 2020 and June 2021. Patients’ age range was from 1 month to 90 years of age with an average age of 41.8 years. Of the 556 patients, 481 (86.5%) were adult patients and 75 (13.5%) were pediatric patients. with an overall male to female ratio of 1:1.04.  Patients arriving at AVH with any signs of respiratory symptoms, were simultaneously evaluated for the presence of SARS-CoV-2 antigens by Panbio TM COVID-19 Ag Rapid Test Device and for th...
The takeaway is simple: The Rapid Antigen Test (RAT) used here had a sensitivity of 69.6%.

Sensitivity is the *true positive* rate. This means that, out of the patients who tested positive for SARS-CoV-2 using qRT-PCR testing, only 69.6% were *also* positive on the RAT.

3/ "Results Panbio TM COVID-19 Test Device clinical sensitivity and specificity  Of the 556 patient’s analyzed NPS, 112 (20.1%) samples were positive by the Allplex TM SARSCoV-2 Assay, while 78 (16.3%) were positive by the Panbio TM COVID-19 assay. Thirty-four samples were negative by Panbio TM COVID-19 Ag Rapid Test Device and positive by the Allplex TM SARS-CoV-2 Assay. Thus, the overall sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were, 69.6%, 100%, 100%, and 92.9%, respectively."  ---  Characteristics of Panbio Rapid Antigen Test ...
Additionally, specificity (true negative rate) of the RAT is 100%, which means that 100% of the patients who were negative on the qRT-PCR were also negative on the RAT.

However, we can also consider these values from a totally different (probabalistic) perspective...

4/ /var/folders/yr/_gzpb_gd2457k8yvz52dbrrh0000gn/T/images/Obsidian 2024-08-03 21.54.38.png
Positive and negative predictive values (PPV & NPV) reflect how well a test predicts a condition.

PPV is, essentially, the probability a positive TEST result predicts an actual positive COVID case.

Here, positive RATs had a 100% chance of accurately predicting a COVID case.

5/ The positive predictive value (PPV) of rapid antigen tests is 100%. This means that a positive RAT results predicts a TRUE underlying COVID case 100% of the time.
NPV is, conversely, the probability a negative TEST result predicts an actual negative COVID status.

In this study, negative RAT only had a 92.9% chance of accurately predicting a negative final diagnosis for COVID.

So why four different numbers? What the hell do they mean?

6/ Image
It'll actually be easier to explain the statistics if we derive them from scratch! These stats are calculated with simple arithmetic!

So, I started by loading the data into a set of descriptively-named variables we can use for the calculation:

7/ # Testing outcomes of 556 patients PCR+ & RAT+ cases = 78 patients PCR- & RAT+ cases = 0 patients PCR+ & RAT- cases = 34 patients PCR- & RAT- cases = 444 patients  # Distribution of RAT testing outcomes all RAT+ cases = (PCR+ & RAT+ cases) + (PCR- & RAT+ cases) = 78 all RAT- cases = (PCR+ & RAT- cases) + (PCR- & RAT- cases) = 478  # Distribution of PCR testing outcomes all PCR+ cases = (PCR+ & RAT+ cases) + (PCR+ & RAT- cases) = 112 all PCR- cases = (PCR- & RAT+ cases) + (PCR- & RAT- cases) = 444 total tested = all PCR+ cases + all PCR- cases = 556
Another way to think of sensitivity is that it's the TRUE POSITIVES detected by RATs, as a fraction of the TOTAL PCR POSITIVES, which is the "gold standard" test, in this case.

(Specificity is more relevant than here if/when there is higher risk of false positives.)

8/ Calculations for Sensitivity & Specificity  # Sensitivity sensitivity = (true positives) ÷ (true positives + false negatives) sensitivity = PCR+ & RAT+ cases ÷ (PCR+ & RAT+ cases + PCR+ & RAT- cases)  Sensitivity of RATs (relative to PCR): 69.6%  # Specificity specificity = (true negatives) ÷ (true negatives + false positives) specificity = PCR- & RAT- cases ÷ (PCR- & RAT- cases + PCR- & RAT+ cases)  Specificity of RATs (relative to PCR): 100%
PPV and NPV differ from the above in that they're derived from Bayes' theorem, and they factor the baseline positivity rate of the tested sample into the calculation.

In this study, the prevalence of COVID among the tested sample was 20.1%.

9/ Calculations for Prevalence  # Prevalence prevalence = (positives) ÷ (positives + negatives) prevalence = (all PCR+ cases) ÷ (total tested)  Prevalence of COVID during test period (as measured by PCR): 20.1%  This means that, out of everyone who was tested, 20.1% were positive via PCR testing. This is our baseline positivity rate within the tested population.
We can use the sensitivity, specificity, and prevalence values we calculated above to derive the PPV and NPV.

THIS is why the accuracy of diagnostic tests decreases as the population-level positivity rate increases: Significant interaction between prevalence and accuracy!

10/ # Positive predictive value (PPV) The formula for PPV is derived from Bayes' theorem: PPV = (sensitivity × prevalence) ÷ (sensitivity × prevalence + (1 - specificity) × (1 - prevalence))  Positive predictive value of RATs for predicting a true COVID case: 100%  ---  # Negative predictive value (NPV) The formula for NPV is derived from Bayes' theorem: NPV = (specificity x (1 - prevalence)) ÷ (specificity × (1 - prevalence) + (1 - sensitivity) × prevalence)  Negative predictive value of RATs for predicting a true non-COVID case: 92.9%
False Omission Rate is the inverse of Negative Predictive Value. This means the probability of a COVID case being missed by a RAT—at the population level—is 7.1% *when you factor in prevalence*!

The probability of tests on different days both missing a COVID case is 0.5%.

11/ # False omission rate (FOR) FOR = 1 - NPV as % = 7.1% Probability of true COVID case being missed: 7.1% Probability of true COVID case being missed twice: 0.5%  Probability that a RAT result will be negative even if the person is actually positive for COVID: 7.1%  Probability that two RAT results will be negative (on separate days) even if the person has COVID: 0.5%
Why is prevalence part of the calculation? Let's see how it impacts the outcome.

Here are the PPV and NPV calculations for tests for hypothetical conditions which affect:

1. 100% of the population
2. 80% of the population
3. 50% of the population
4. 0% of the population

12/ Example: 100% prevalence - PPV: 100% - NPV: 0%  If 100% of the population has some condition, then a negative test result is incorrect, by definition!  ---  Example: 80% prevalence - PPV: 100% - NPV: 45.2%  If the prevalence in the population is very high, then a negative result is much more likely to be wrong.  ---  Example: 50% prevalence - PPV: 100% - NPV: 76.7%  ---  Example: 0% prevalence - PPV: division by zero error - NPV: 100%  If a condition were eliminated from the population, we can (probably) assume that a positive test result is actually a false positive (if it's like... smallp...
And now you can see why you need to have two negatives, two days in a row on rapid antigen tests to consider it a true negative: variable likelihood of *what* is causing your symptoms, *when* you were infected relative to today, etc., means false negatives vary!

13/
Anyway, back to the paper! In qRT-PCR testing, the Ct value is a "relative measure of the concentration of target in the PCR reaction."

That is, it's an arbitrary value that is *consistently meaningful* for all machines running this specific test.

14/
Figure 1. Graphical representation of real-time PCR data. Rn is the fluorescence of the reporter dye divided by the fluorescence of a passive reference dye; i.e.,Rn is the reporter signal normalized to the fluorescence signal of Applied Biosystems ™ ROXtM Dye. (A) In this view, Rn is plotted against PCR cycle number. (B) ARn is Rn minus the baseline; ARn is plotted against PCR cycle number. (C) An amplification plot shows the variation of log (ARn) with PCR cycle number.  Source: https://www.thermofisher.com/ca/en/home/life-science/pcr/real-time-pcr/real-time-pcr-learning-center/real-time-p...
Factors that can influence Ct  Ct (threshold cycle) is the intersection between an amplification curve and a threshold line. It is a relative measure of the concentration of target in the PCR reaction. Many factors impact the absolute value of Ct besides the concentration of the target. We will discuss the most common template-independent factors that can influence Ct and describe how to evaluate the performance of a real-time PCR reaction.  The exponential phase in Figure 1B corresponds to the linear phase in Figure 1C. ... The Ct value increases with a decreasing amount of template. Howev...
This study found that if the qRT-PCR threshold was set to a value of 20—indicating the positivity threshold was crossed after 20 or fewer amplification cycles—the sensitivity of RATs was 91.8%.

RAT sensitivity dropped to 77.5% for those with PCR positivity between 20-30 Ct!

15/ "Panbio COVID-19 Test Device detection limit based on qRT-PCR assay Ct value  Stratifying the positive SARS-CoV-2 samples by the qRT-PCR Ct value, revealed that the Panbio TM COVID-19 Ag Rapid Test Device performed well with a high sensitivity (91.8%) when the qRT-PCR Ct value was below 20. The Panbio COVID-19 Ag Rapid Test Device sensitivity dropped to 77.5% in patient samples with a Ct value 20–30. The Panbio TM COVID-19 Ag Rapid Test Device performance was very poor in samples with qRT-PCR Ct values between 30–34 and 35–40, 18.2% and 0%, respectively."
What does it mean? Well, a lower qRT-PCR Ct value corresponds to *higher* viral load, so in an immunocompromised group (oncology patients), RATs are *somewhat* reliable at detecting COVID cases.

In this patient group, viral load skewed higher (indicated by lower Ct values).

16/ Table 2. Ct values and Panbio COVID-19 Ag rapid test results.  Ct / Antigen positive / Antigen negative / Total / Percent (%) Less than 20 / 45 / 4 / 49 / 91.8 20-29 / 31 / 9 / 40 / 77.5 30-34 / 2 / 9 / 11 / 18.2 35-40 / 0 / 12 / 12 / 0  https://doi.org/10.1371/journal.pone.0306396.t002
The biggest caveat to this study is that they didn't have symptom info for all cases. This can had an impact on the effectiveness of RATs: "Most studies agree on the fact that RAT can be mostly reliable in patients with respiratory symptoms and not asymptomatic individuals"

17/ "P-Value of 0.007 indicates that our hypothesis that the difference between rapid test results of COVID-19 samples versus PCR test is statistically significant. However, PCR testing is more sensitive and might be considered in rapid test negative cases if it is still suspected to have a positive result through PCR based on symptoms or exposure to infected individuals.  In our study, one of the main limitations was that symptoms were not reported for all cases, a previous study showed that RAT sensitivity was 34% in an emergency department with 421 patients participating in the study. O...
What's the takeaway? If we're following the precautionary principle:

- RATs shouldn't be relied upon for *ruling out* infections.
- RATs still CAN be used to quickly and effective *rule in* an infection.

18/ "Conclusion  Based on the results obtained in this research, and other similar studies, it can be concluded that using qRT-PCR testing in asymptomatic patients is preferred, while in symptomatic patients antigen testing somehow showed positive results that can be used to make fast and effective decisions regarding the isolation of patients and preventing outbreaks in hospital setting, thus we recommend performing RT-PCR in patients with negative results that are highly suspected to have Covid- 19 afterwards."
Note that the data in the paper is pre-Omicron. On top of that, the RAT used here requires a nasopharyngeal swab to be taken by a professional.

All that is to say that the numbers here should probably be taken as the UPPER BOUNDARY for RAT reliability in the Omicron era.

19/
IMO, the reliability of RATs is probably much lower today, because:

- self-tests already have a lower reliability, and
- other studies have shown that Omicron seems to produce lower levels of antigen presentation.

Both of those could increase the false negative rate.

20/
Why is there such a big difference between RAT and PCR sensitivity? They work in fundamentally different ways!

qRT-PCR detects the presence of genes which encode: 1) the enzyme the virus uses to replicate, 2) the nucleocapsid gene, 3) the envelope gene.

21/ "Abbott Panbio COVID-19 Rapid Test Device.  This lateral flow assay (LFA) is intended to rapidly detect SARS-CoV-2 Antigen in the patient's nasopharyngeal swab within 15 minutes. The Panbio COVID-19 Ag Rapid Test Device is a chromatography assay that contains a membrane strip that is pre-coated with immobilized anti-SARS-CoV-2 antibody on the test line...  Seegene Allplex SARS-CoV-2 Assay.  The FDA-EUO-approved multiplex qRT-PCR was designed to detect three SARS-CoV-2 target genes and one internal control gene in a single reaction tube within 3-4 hours. The assay detects SARS-CoV-2 spe...
For this rapid antigen test, in contrast, the test line is coated with an anti-SARS-CoV-2 antibody, which reacts with a SARS-CoV-2 antigen.

The control line is coated with an anti-chicken IgY antibody, and the buffer solution contains a chicken IgY protein to react with.

22/ "The Panbio™ COVID-19 Ag Rapid Test Device is a chromatography assay that contains a membrane strip that is pre-coated with immobilized anti-SARS-CoV-2 antibody on the test line and mouse monoclonal anti-chicken IgY on the control line. Human IgG gold conjugate specific to SARS-CoV-2 Ag and chicken IgY gold conjugate move upwards on the membrane chromatographically and react with anti-SARS-CoV antibody and pre-coated mouse monoclonal anti-chicken IgY, respectively. The presence of SARS-CoV-2 antigen in the patient sample will be indicated by the development of a test line in the result...
So while RNA from SARS-CoV-2 genes is *amplified* in qRT-PCR testing to allow even small amounts of RNA to be detected, rapid antigen tests just have to work with whatever is on the swab. If the right antigen isn't at the swab location, the test will be negative!

23/
If we were still in a world that practiced basic infection control, this study would have confirmed that rapid antigen tests are an effective measuring for rapidly detecting infections, to minimize exposure as much as possible.

24/ "Role of the utilization of the Panbio COVID-19 Test Device in infection control  The rapid turnaround time of the Panbio COVID-19 Ag Rapid Test Device allowed the infection control (IC) team to make quick decisions and move the infected patients to the COVID-19 center on 69.6% of the SARS-CoV-2 patients within 30 minutes of the patient's arrival to the hospital avoiding causing SARS-CoV-2 hospital-acquired infections. However, the presence of negative Panbio COVID-19 Ag Rapid Test in patients with very high viral titers (low Ct value) mandates keeping careful attention to the patient'...
This thread ended up being more of a statistics lesson than anything, which I'll definitely be linking to a whole bunch.

The paper was published on August 2, 2024 in PLOS ONE, and is available open access:

25/25journals.plos.org/plosone/articl…

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Nick #RespiratorsFilterPathogens😷 Anderegg

Nick #RespiratorsFilterPathogens😷 Anderegg Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @NickAnderegg

Aug 4
New preprint on the PATHOGENICITY of H5N1 was published yesterday, and... it's not good news, but it's definitely not *terrible* news either!

The delayed, lackluster response to the current outbreak remains DEEPLY concerning.

Here's a summary for a general audience!

1/many
Preprint published August 3, 2024: "Enhanced replication of contemporary human highly pathogenic avian influenza H5N1 virus isolate in human lung organoids compared to bovine isolate"  Abstract  "We compared virus replication and host responses in human alveolar epithelium infected with highly pathogenic avian influenza (HPAI) H5N1 viruses. A/Vietnam/1203/2004 replicated most efficiently, followed by A/Texas/37/2024, then A/bovine/Ohio/B240SU342/2024. Induction of interferon-stimulated genes was lower with A/Texas/37/2024 and A/bovine/Ohio/B24OSU-342/2024, which may indicate ...
They test three H5N1 isolates. I'll refer to them as:

- Texas: Isolated from worker at Texas dairy farm (A/Texas/37/2024)
- Bovine: Isolated from dairy cow (A/bovine/Ohio/B24OSU-342/2024)
- Vietnam: Isolated from fatal 2004 human infection in Vietnam (A/Vietnam/1203/2004)

2/
"As of July 25, 2024, 13 human cases of HPAI H5N1 virus infection have been confirmed in the United States (3). Several of these cases are linked to exposure to infected cattle. However, recent outbreaks in Colorado have resulted in identification of additional human cases linked to infected poultry (3). Virus isolated from a worker at a Texas dairy farm (A/Texas/37/2024) was shown to be closely related to viruses circulating in cattle, and it is presumed that this case is a result of direct cow-to-human transmission (4). Reported symptoms included conjunctivitis, as well as mild respi...
"This is in stark contrast to prior cases of HPAI H5N1 virus infection in humans, which resulted in severe respiratory disease and mortality rates upwards of 50% (6). In order to assess the risk of developing severe disease following infection with contemporary HPAI H5N1 virus, we evaluated virus replication, host cell survival, and induction of innate immune responses in human alveolar epithelium infected with A/Texas/37/2024 or cattle isolate A/bovine/Ohio/B24OSU-342/2024, compared to a historical H5N1 isolate A/Vietnam/1203/2004, which was derived from a fatal human case (7)."
This study looked at pathogenicity, which is, basically, the ability of a virus to fuck up your cells, organs, or body, as determined by some measurable indicator of damage.

It's one of those concepts that's so broad that it's useful to include a formal definition:

3/
NIH > National Library of Medicine  MeSH (Medical Subject Headings)  Virulence (synonym-ish for "pathogenicity")  The degree of pathogenicity within a group or species of microorganisms or viruses as indicated by case fatality rates and/or the ability of the organism to invade the tissues of the host. The pathogenic capacity of an organism is determined by its VIRULENCE FACTORS.
NIH > National Library of Medicine  MeSH (Medical Subject Headings)  Virulence (Preferred):  The degree of pathogenicity within a group or species of microorganisms or viruses as indicated by case fatality rates and/or the ability of the organism to invade the tissues of the host. The pathogenic capacity of an organism is determined by its VIRULENCE FACTORS.  Pathogenicity (Related):  The capacity of a microorganism to cause disease.
Read 17 tweets
Jul 29
Let me start by saying AAAAAAAAAAAAAAAAAAAAAA.

Turns out SARS-CoV-2 RAPIDLY infects the NERVOUS SYSTEM long BEFORE it even enters the bloodstream.

These findings have huge implications! Here's an analysis of the study, written for a general audience. (Sorry in advance!)

1/many Published July 28, 2024 in IJMS: "SARS-CoV-2 Rapidly Infects Peripheral Sensory and Autonomic Neurons, Contributing to Central Nervous System Neuroinvasion before Viremia"  Abstract: "...little attention has been paid to susceptibility of the PNS to infection [by SARS-CoV-2] or to its contribution to CNS invasion. Here we show that sensory and autonomic neurons in the PNS are susceptible to productive infection with SARS-CoV-2 and outline physiological and molecular mechanisms mediating neuroinvasion. Our infection of K18-hACE2 mice, wild-type mice, and golden Syrian hamsters...
Overall, it's pretty extensive: They examined the productivity of neuronal infection in multiple animal models and multiple neuronal cell cultures, and found productive neuronal infection across the board.

It's also a long one, but we'll pick up the pace as we go!

2/ Figure 3. SARS-CoV-2 infection of the olfactory bulb and various brain regions in hACE2 and WT mice. SARS-CoV-2 RNA was detected in increasing concentrations from 3 to 6 dpi in the olfactory bulb (a), hippocampus (b), cortex (c), brainstem (d), and cerebellum (e) of hACE2 and WT mice in both inoculum groups.
So, as you may already know, neurological symptoms are actually VERY common when it comes to COVID, with several different types of neurological issues being notable features of Long COVID. There's seriously so much evidence beyond these 13 citations!

3/ "Up to 80% of people infected with SARS-CoV-2, the virus responsible for COVID-19, report neurological symptoms. ... including [with] sensory and autonomic systems [1–3]. Both central and peripheral symptoms, such as fatigue, memory issues, “brain fog”, hyper/hypoesthesia, and autonomic dysfunction, can persist as part of postCOVID-19 syndrome (“long COVID”) long after acute infection [4]. Detection of the virus, viral RNA, and antigens in the cerebrospinal fluid and brains of COVID-19 patients indicates SARS-CoV-2 is neuroinvasive, which has also been documented for common cold and ep...
Read 37 tweets
Jul 28
Big picture, these findings are bad for EVERYBODY, but ESPECIALLY for those still clinging to the fantasy of "natural immunity."

The takeaway? It's unclear if ANYONE has strong immunity to COVID infection!

Here's a deep analysis thread, written for a general audience!

1/many Published July 26, 2024 in Nature Medicine: "SARS-CoV-2 correlates of protection from infection against variants of concern"  Abstract: "Serum neutralizing antibodies (nAbs) induced by vaccination have been linked to protection against symptomatic and severe COVID-19. However, much less is known about the efficacy of nAbs in preventing the acquisition of infection, especially in the context of natural immunity and against SARS-CoV-2 immune-escape variants. Here we conducted mediation analysis to assess serum nAbs induced by prior SARS-CoV-2 infections as potential correlates ...
The paper is fairly complex, but the takeaways are pretty straightforward, so I'll start with the highlights!

Method is robust, data collection was EXTENSIVE: It's a longitudinal study (follows the same individuals over time) with regular nasal swabs and blood draws!

2/ Figure 1: "Timing of cohort sample collections with respect to SARS-CoV-2 variants’ circulations in the two study sites. a, Timing of the blood draws with respect to the SARS-CoV-2 epidemic waves in the rural site (Agincourt) of the PHIRST-C cohort. The bar plot represents the weekly incidence (per 100,000 population) of SARS-CoV-2 cases from routine surveillance data collected from the Ehlanzeni district in the Mpumalanga province (where rural participants reside). The shaded areas represent the timing of the serum sample collections for the ten blood draws. Each curve within the shad...
Because they have blood draws from just before each wave, it's the perfect data to examine the immunity conferred by prior infections.

Because South Africa had a low vaccination rate at the beginning of Omicron, this is also great data for examining natural immunity!

3/ [Note: The 1st wave (Alpha) is referred to as D614G throughout the paper. The 4th wave (Omicron) is referred to as Omicron.]  "This high-intensity sampling scheme allowed us to reconstruct the cohort participants’ SARS-CoV-2 infection histories with high fidelity, and to monitor infection-induced antibody responses over time. Blood samples collected immediately before Delta and Omicron waves offered a unique opportunity to investigate serum immune marker levels in close proximity to the next SARS-CoV-2 exposure. Furthermore, vaccine-derived immunity remained low at the onset of the Omi...
Read 30 tweets
Jul 24
This preprint seems HUGE: It has CONCRETE DIAGNOSTIC CRITERIA for a specific subtype of LC!

The novel disease identified here is named "SARS-CoV-2 Persistent Intestinal* Epithelial Syndrome (SPIES)"!

Gastrointestinal LC has a new name! Thread, for a general audience...

1/20 Identification of SARS-CoV-2 Persistent Intestinal* Epithelial Syndrome (SPIES) as a Novel Disease Entity using Clinical, Histologic, and RNA Programmatic Data  The "Infectious" in the title is a typo, as they use "Intestinal" in the rest of the paper. I guess they were also excited to get it posted!
I love this preprint because, not only does it make a specific subtype of LC into a tangible medical artifact, but it also identifies the way in which SPIES differs from similar conditions, like IBS!

2/
GI issues following a COVID infection have been known for a long time, and gastrointestinal Long COVID is one of the more prevelant issues among the total population.

Because there is the possibility of viral persistence, that's what they examined here.

3/ "... The impact of gastrointestinal LC has been substantial, and to date is relatively poorly understood. Prior work has identified a trend towards increasing pediatric inflammatory bowel disease (IBD) since the emergence of COVID', , the ability of SARS-CoV-2 to persist in the gut?, 3, as well as increased risk of liver disease, demonstrating capacity of this infection to induce durable gastrointestinal complications. Overall, 10-25% of patients report Gl symptoms (nausea, anorexia, weight loss, diarrhea, hematochezia) 6 months following infection'. Given previous work suggesting rate...
Read 21 tweets
Jul 23
FIRST: This paper DOES NOT HAVE CLINICAL VALUE. It is NOT about treatment!

With that out of the way: WOW, WOW, WOOOW.

"After six years, 44.1% of the [ME/CFS patients treated with cyclophosphamide] scored an SF-36 PF of at least 70, and 17.6% of at least 90..."

Summary ⬇️

1/13 CAVEAT: These findings have NO practical use outside of a research setting! "Cyclophosphamide... should not be used for ME/CFS patients outside of clinical trials."  Conclusions:  "After six years, 44.1% of the cyclophosphamide group scored an SF-36 PF of at least 70, and 17.6% of at least 90, suggesting that cyclophosphamide in a subgroup may modulate the disease course in a beneficial way. However, cyclophosphamide carries toxicity concerns and should not be used for ME/CFS patients outside clinical trials. Rather, these data should encourage efforts to better understand th...
The clinical trials (conducted last decade) were based on the hypothesis that a subset of ME/CFS patients are experiencing an autoimmune condition; this study is the six-year follow-up!

The interesting result here is the impact of cyclophosphamide (from the CycloME trial)

2/ Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome  Abstract:  "Objectives  In this six-year follow-up study, we used patient-reported outcome measures (PROMs) to compare values at baseline, at 18 months, and at six-year follow up from the CycloME and the RituxiME trials.  Methods  Based on the hypothesis that ME/CFS in a subgroup of patients is a variant of an autoimmune disease, we performed two clinical trials between 2014 and 2017. The RituxVE trial was a randomized, double-blind and place...
Here's the major takeaway: "In the CycloME trial, mean SF-36 PF increased from 35.4 at baseline to 54.4 at 18 months, and 56.7 at six years."

At six years, 44% of the CycloME group had an SF-36 PF ≥ 70, and 18% had an SF-36 PF ≥ 80 "which is within normal range."

3/ Abstract:  "Result  Of the patients available after six years, 75.7% of RituxME and 94.4% of CycloME patients participated.  In the RituxME rituximab group, the mean SF-36 PF scores were 32.9 at baseline, 42.4 at 18 months and 45.5 at six years. In the placebo group, the mean SF-36 PF scores were 32.3 at baseline, 45.5 at 18 months and 43.1 at six years.  In the CycloME trial, mean SF-36 PF increased from 35.4 at baseline to 54.4 at 18 months, and 56.7 at six years. At six-year follow-up, 44.1% of cyclophosphamide-, 27.6% of rituximab- and 20.4% of placebo-treated patients had an SF-36...
Read 14 tweets
Jul 19
An interesting re-analysis was published today: "Remdesivir treatment does not reduce viral titers in patients with COVID-19"

Basically, remdesivir has no impact on *viral load* in acute COVID!

Here's a summary of the findings—and controversy—for a general audience!

1/12 Remdesivir treatment does not reduce viral titers in patients with COVID-19  "ABSTRACT  The relationship (or lack thereof) between the clinical activity of remdesivir and its ability to reduce viral titers in patients with COVID-19 has not been fully delineated. There is a misconception that remdesivir was FDA-approved for COVID-19 due to its ability to reduce viral titers. Here, we analyze all clinical studies of remedesivir in COVID-19 that quantifed SARS-CoV-2 titers. As of 28 June 2024, we show there is no significant decrease in SARS-CoV-2 viral titers in patients treted with remd...
Initially, remdesivir received emergency FDA approval because in one NIH-sponsored trial, the remdesivir group recovered quicker than the control group. That's ALL.

It was trialed because it does seem to be a great drug in cell cultures in the lab!

2/
"Remdesivir (RDV) was the first FDA-approved treatment for COVID-19 based on results from the NIH-sponsored ACTT-1 trial demonstrating shorter time to recovery in patients with severe COVID-19 treated with remdesivir compared to placebo (10 vs 15 days, respectively) (1). While RDV demonstrated benefit in ACTT-1, its efficacy and clinical benefit have been marginal-to-ineffective in other contexts, making its FDA approval controversial. Several subsequent randomized controlled trials (RCTs) found no benefit with RDV treatment compared to placebo or the standard of care (SOC) (2-4), incl...
"Marginal clinical benefit with RDV treatment calls into question whether there is a relationship between the mechanism of viral load inhibition with RDV treatment and corresponding clinical outcomes. RDV is a prodrug of an ATP-analogue (GS-443902) that exhibits broad-spectrum antiviral activity (5). GS-443902 exhibits low Km for SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and cell-based assays have demonstrated low nanomolar EC50 values in SARS-CoV-2 infected cells treated with remdesivir (68)(9). Cells infected with SARS-CoV-2 and treated with remdesivir in vitro also show dose-de...
It SEEMED like it would be a great drug, because it does exactly what we want *in cell cultures*. Unfortunately, even in animal models, it seemingly had issues.

In particular, viral load was lower in fluid from the lungs, but not in nose, throat, or rectal swabs.

3/ "The preclinical pharmacodynamics of remdesivir have been extensively well-validated; it thus stands to reason that the observed decreases in viral load should translate in the clinic. If remdesivir demonstrates clinical benefit, it would stand to reason that there is a concomitant decrease in viral load associated with remdesivir treatment. However, this was not the case.  Limited pharmacodynamic activity of RDV in humans was foreshadowed by the weak reductions in viral titers observed in rhesus macaque models of COVID-19 (11). Treatment with RDV lead to statistically significant decr...
Read 12 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(